Matches in SemOpenAlex for { <https://semopenalex.org/work/W1837457249> ?p ?o ?g. }
- W1837457249 abstract "This phase II study evaluated the efficacy and safety of gemcitabine (G) plus paclitaxel (T) as first-line therapy in recurrent or metastatic breast cancer. Patients with locally, recurrent or metastatic breast cancer and no prior chemotherapy for metastatic disease received G 1200 mg/m2 on days 1 and 8, and T 175 mg/m2 on day 1 (before G) every 21 days for a maximum of 10 cycles. Forty patients, 39 metastatic breast cancer and 1 locally-advanced disease, were enrolled. Their median age was 61.5 years, and 85% had a World Health Organization performance status (PS) of 0 or 1. Poor prognostic factors at baseline included visceral involvement (87.5%) and ≥2 metastatic sites (70%). Also, 27 (67.5%) patients had prior adjuvant chemotherapy, 25 of which had prior anthracyclines. A total of 220 cycles (median 6; range, 1–10) were administered. Of the 40 enrolled patients, 2 had complete response and 12 partial response, for an overall response rate of 35.0% for intent-to-treat population. Among 35 patients evaluable for efficacy the response rate was 40%. Additional 14 patients had stable disease, and 7 had progressive disease. The median duration of response was 12 months; median time to progression, 7.2 months; median survival, 25.7 months. Common grade 3/4 toxicities were neutropenia in 17 (42.5%) patients each, grade 3 leukopenia in 19 (47.5%), and grade 3 alopecia in 30 (75.0%) patients; 1 (2.5%) patient had grade 4 thrombocytopenia. GT exhibited encouraging activity and tolerable toxicity as first-line therapy in metastatic breast cancer. Phase III trials for further evaluation are ongoing." @default.
- W1837457249 created "2016-06-24" @default.
- W1837457249 creator A5003536346 @default.
- W1837457249 creator A5012336750 @default.
- W1837457249 creator A5023813062 @default.
- W1837457249 creator A5046156275 @default.
- W1837457249 creator A5061807618 @default.
- W1837457249 creator A5065561614 @default.
- W1837457249 creator A5085315048 @default.
- W1837457249 creator A5089850702 @default.
- W1837457249 date "2005-11-29" @default.
- W1837457249 modified "2023-10-16" @default.
- W1837457249 title "First-line therapy with gemcitabine and paclitaxel in locally, recurrent or metastatic breast cancer: A phase II study" @default.
- W1837457249 cites W1520702439 @default.
- W1837457249 cites W1812067939 @default.
- W1837457249 cites W18214132 @default.
- W1837457249 cites W1898871412 @default.
- W1837457249 cites W1946759281 @default.
- W1837457249 cites W1971473564 @default.
- W1837457249 cites W1997838307 @default.
- W1837457249 cites W1999879350 @default.
- W1837457249 cites W1999982168 @default.
- W1837457249 cites W2009930501 @default.
- W1837457249 cites W2010341976 @default.
- W1837457249 cites W2013246214 @default.
- W1837457249 cites W2037605675 @default.
- W1837457249 cites W2044573147 @default.
- W1837457249 cites W2045316633 @default.
- W1837457249 cites W2067120001 @default.
- W1837457249 cites W2068532424 @default.
- W1837457249 cites W2069588715 @default.
- W1837457249 cites W2083470546 @default.
- W1837457249 cites W2128848742 @default.
- W1837457249 cites W2131770017 @default.
- W1837457249 cites W2133243551 @default.
- W1837457249 cites W2139861053 @default.
- W1837457249 cites W2143989581 @default.
- W1837457249 cites W2157800681 @default.
- W1837457249 cites W2169073956 @default.
- W1837457249 cites W2178225042 @default.
- W1837457249 cites W2182111422 @default.
- W1837457249 cites W2294342511 @default.
- W1837457249 cites W2329401292 @default.
- W1837457249 cites W37295386 @default.
- W1837457249 cites W4255152173 @default.
- W1837457249 doi "https://doi.org/10.1186/1471-2407-5-151" @default.
- W1837457249 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/1315334" @default.
- W1837457249 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16316459" @default.
- W1837457249 hasPublicationYear "2005" @default.
- W1837457249 type Work @default.
- W1837457249 sameAs 1837457249 @default.
- W1837457249 citedByCount "22" @default.
- W1837457249 countsByYear W18374572492015 @default.
- W1837457249 countsByYear W18374572492016 @default.
- W1837457249 countsByYear W18374572492019 @default.
- W1837457249 countsByYear W18374572492022 @default.
- W1837457249 crossrefType "journal-article" @default.
- W1837457249 hasAuthorship W1837457249A5003536346 @default.
- W1837457249 hasAuthorship W1837457249A5012336750 @default.
- W1837457249 hasAuthorship W1837457249A5023813062 @default.
- W1837457249 hasAuthorship W1837457249A5046156275 @default.
- W1837457249 hasAuthorship W1837457249A5061807618 @default.
- W1837457249 hasAuthorship W1837457249A5065561614 @default.
- W1837457249 hasAuthorship W1837457249A5085315048 @default.
- W1837457249 hasAuthorship W1837457249A5089850702 @default.
- W1837457249 hasBestOaLocation W18374572491 @default.
- W1837457249 hasConcept C121608353 @default.
- W1837457249 hasConcept C126322002 @default.
- W1837457249 hasConcept C141071460 @default.
- W1837457249 hasConcept C143998085 @default.
- W1837457249 hasConcept C2775930923 @default.
- W1837457249 hasConcept C2776694085 @default.
- W1837457249 hasConcept C2777063308 @default.
- W1837457249 hasConcept C2778822529 @default.
- W1837457249 hasConcept C2779984678 @default.
- W1837457249 hasConcept C2780140570 @default.
- W1837457249 hasConcept C2780258809 @default.
- W1837457249 hasConcept C2780873365 @default.
- W1837457249 hasConcept C2908647359 @default.
- W1837457249 hasConcept C31760486 @default.
- W1837457249 hasConcept C530470458 @default.
- W1837457249 hasConcept C71924100 @default.
- W1837457249 hasConcept C90924648 @default.
- W1837457249 hasConcept C99454951 @default.
- W1837457249 hasConceptScore W1837457249C121608353 @default.
- W1837457249 hasConceptScore W1837457249C126322002 @default.
- W1837457249 hasConceptScore W1837457249C141071460 @default.
- W1837457249 hasConceptScore W1837457249C143998085 @default.
- W1837457249 hasConceptScore W1837457249C2775930923 @default.
- W1837457249 hasConceptScore W1837457249C2776694085 @default.
- W1837457249 hasConceptScore W1837457249C2777063308 @default.
- W1837457249 hasConceptScore W1837457249C2778822529 @default.
- W1837457249 hasConceptScore W1837457249C2779984678 @default.
- W1837457249 hasConceptScore W1837457249C2780140570 @default.
- W1837457249 hasConceptScore W1837457249C2780258809 @default.
- W1837457249 hasConceptScore W1837457249C2780873365 @default.
- W1837457249 hasConceptScore W1837457249C2908647359 @default.
- W1837457249 hasConceptScore W1837457249C31760486 @default.
- W1837457249 hasConceptScore W1837457249C530470458 @default.
- W1837457249 hasConceptScore W1837457249C71924100 @default.